Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support.
Johnsen HE, Björkstrand B, Carlson K, Gruber A, Blystad A, Fast A, Boesen AM, Björkholm M, Sallerfors B, Ruutu T, Carneskog J, Malm A, Geisler C, Lehtinen M, Schrøder H, Brinch L, Remes K, Tidefelt U, Heilmann C, Hörnsten P, Thorling K, Daugaard G. Johnsen HE, et al. Among authors: boesen am. Leuk Lymphoma. 1996 Dec;24(1-2):81-91. doi: 10.3109/10428199609045716. Leuk Lymphoma. 1996. PMID: 9049964
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML.
de Nully Brown P, Hoffmann T, Hansen OP, Boesen AM, Grønbaek K, Hippe E, Jensen MK, Thorling K, Storm HH, Pedersen-Bjergaard J. de Nully Brown P, et al. Among authors: boesen am. Leukemia. 1997 Jan;11(1):37-41. doi: 10.1038/sj.leu.2400514. Leukemia. 1997. PMID: 9001416 Clinical Trial.
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB, et al. Hansen OP, et al. Among authors: boesen am. Leukemia. 1991 Jun;5(6):510-6. Leukemia. 1991. PMID: 2056774 Clinical Trial.
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).
Geisler CH, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Nilsson-Ehle H, Kuittinen O, Lauritzsen GF, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group. Geisler CH, et al. Among authors: boesen am. Blood. 2010 Feb 25;115(8):1530-3. doi: 10.1182/blood-2009-08-236570. Epub 2009 Dec 23. Blood. 2010. PMID: 20032504 Free article. Clinical Trial.
40 results